Background-Long-term comparative data of first-generation drug-eluting stents are scarce. We investigated clinical and angiographic outcomes of sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) at 5 years as part of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) LATE study. Methods and Results-A total of 1012 patients were randomly assigned to SES or PES. Repeat angiography was completed in 444 of 1012 patients (43.8%) at 5 years. Major adverse cardiac events occurred in 19.7% of SES-and 21.4% of PES-treated patients (hazard ratio, 0.89; 95% confidence interval, 0.68 to 1.17; Pϭ0.39) at 5 years. There were no differences between SES and PES in terms of cardiac death (5.8% versus 5.7%; Pϭ0.35), myocardial infarction (6.6% versus 6.9%; Pϭ0.51), and target lesion revascularization (13.1% versus 15.1%; Pϭ0.29). Between 1 and 5 years, the annual rate of target lesion revascularization was 2.0% (95% confidence interval, 1.4% to 2.6%) for SES and 1.4% (95% confidence interval, 0.9% to 2.0%) for PES. Among patients undergoing paired angiography at 8 months and 5 years, delayed lumen loss amounted to 0.37Ϯ0.73 mm for SES and 0.29Ϯ0.59 mm for PES (Pϭ0.32). The overall rate of definite stent thrombosis was 4.6% for SES and 4.1% for PES (Pϭ0.74), and very late definite stent thrombosis occurred at an annual rate of 0.65% (95% confidence interval, 0.40% to 0.90%).
delayed healing with differences in pathological phenotypes between SES and PES. 12 However, the differential safety profile of SES and PES during long-term follow-up has not been established. Moreover, the phenomenon of very late ST emerged among more complex patients, 13 and long-term data from randomized trials with the unrestricted use of DES are not available. We therefore extended the clinical and angiographic follow-up of patients included in the all-comers Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) trial to 5 years.
Methods

Study Design and Eligibility Criteria
The design and methods of this randomized, assessor-blind trial have been reported previously. 4 In brief, 1012 patients with Ն1 lesion in a vessel with a reference diameter between 2.25 and 4.00 mm were randomly assigned to treatment with SES or PES. There were no limitations on the number of lesions or vessels or on the length of the lesions. The study complied with the Declaration of Helsinki regarding investigation in humans and was approved by the institutional ethics committees at Bern University Hospital and University Hospital Zurich in Switzerland. All patients provided written informed consent.
Data Collection and Clinical and Angiographic Follow-Up
Adverse events, angina status, and cardiovascular medication intake were assessed in hospital, at 1, 6, and 9 months, and on an annual basis up to 5 years. All patients were asked to return for repeat angiography at 8 months. The results of the primary clinical end point at 9 months and the principal angiographic end point at 8 months have been reported previously. 4 For the purpose of the present study, all patients who had at least 1 study lesion without intervening revascularization during follow-up were invited to undergo another angiographic study between 4 and 5 years of follow-up ( Figure 1 ). All patients were advised to take acetylsalicylic acid indefinitely and clopidogrel for 1 year. 4 
Study End Points and Definitions
An independent clinical events committee unaware of the patients' assignments adjudicated all clinical end points. The primary end point was a composite of major adverse cardiac events (MACE) (cardiac death, MI, and ischemia-driven target lesion revascularization [TLR]) at 9 months. 4 Secondary end points included ischemiadriven TLR, target vessel revascularization or target vessel failure, and MI. Post hoc, all stent thromboses were assessed according to the Academic Research Consortium criteria. Late loss (LL) was defined as the difference between the minimal luminal diameter (MLD) after the procedure and MLD at follow-up. Delayed LL was defined as the difference between MLD at 8 months and MLD at 5 years. The principal secondary end point of the angiographic substudy was delayed LL between 8 months and 5 years among patients undergoing paired angiography.
Quantitative Coronary Angiography
Coronary angiograms were recorded at baseline immediately after the procedure, at 8 months, and at 5 years, and were assessed at the core laboratory of Bern University Hospital. Patients received nitroglycerin before angiography, and measurements were performed on cineangiograms. The contrast-filled, untapered tip of the catheter was used for calibration. Quantitative measurements included reference vessel diameter, MLD, and percent diameter stenosis. Digital angiograms were analyzed with the use of an automated edge-detection system (CAAS II, Pie Medical Imaging). Angiographic readers were unaware of the type of stent implanted. Quantitative coronary angiograms from patients returning for repeat angiography in the setting of stent thrombosis were not included during the first 30 days. However, events beyond 30 days were part of the angiographic analysis because the need for repeat revascularization could no longer be attributed to an acute response of the lesion to the procedure.
Statistical Analyses
All patients were included in the analysis of primary and secondary clinical outcomes. We used the Mantel-Cox method to estimate hazard ratios and 95% confidence intervals for comparisons of clinical outcomes between groups and the log-rank test to calculate corresponding P values. Analyses of outcomes of the angiographic substudy were restricted to patients who returned for 5-year angiographic follow-up. Angiographic data were analyzed for all patients undergoing paired angiography at baseline, 8 months, and 5 years, as well as for all patients undergoing angiography at baseline and 5 years. Study lesions requiring revascularization by either percutaneous coronary intervention or coronary artery bypass grafting between 8 months and 5 years were assessed by quantitative coronary angiography and contributed to the 5-year angiographic analysis. A patient could have had Ͼ1 lesion in which a stent was implanted. Therefore, in the analysis of the quantitative angiographic data, we used maximum-likelihood logistic and linear regression models, crude and adjusted for MLD at baseline, which were based on robust standard errors that allowed for the correlation of multiple lesions within a patient to compare the characteristics of lesion between groups at baseline and follow-up. Trial data were held by the Clinical Trials Unit in Bern. Analyses were performed with the use of Stata software by an analyst who was unaware of the type of stent implanted. No adjustments were made for multiple comparisons in secondary analysis. All P values are 2 sided.
Results
Between April 2003 and May 2004, 1012 patients with 1401 lesions were randomly assigned to treatment with SES or PES. At 5 years, clinical follow-up was available for 491 SES patients (97.6%) and 489 PES patients (96.1%) ( Figure 1 ). Baseline clinical, angiographic, and procedural characteristics were balanced between both groups (Table 1) . Cardiovascular medications at 1 and 5 years are shown in Table I in the online-only Data Supplement.
Clinical Outcomes
Clinical outcomes are summarized in Table 2 . At 1 year, the primary outcome of MACE was lower among SES-(8.3%) than PES-treated patients (13.6%; PϽ0.01). The early difference in favor of SES was driven by a 45% reduction of ischemia-driven TLR (SES 5.8% versus PES 10.2%; PϽ0.01). In contrast, SES was no longer superior to PES in terms of MACE (SES 19.7% versus PES 21.4%; Pϭ0.39) and TLR (SES 13.1% versus PES 15.1%; Pϭ0.29) at 5 years ( Table 2 ). All-cause and cardiac mortality rates were similar among patients treated with SES and PES at 1 and 5 years, as were rates of MI ( Figure 2 ). Landmark analysis beyond 1 year indicated numerically higher event rates of MACE and TLR among patients treated with SES than among patients treated with PES ( Figure 2 ). Differences between SES and PES in terms of MACE and its components stratified for the time period up to 1 year, between 1 and 5 years, and up to 5 years are shown in Figure 3 . Academic Research Consortium definite, probable, and possible stent thrombosis occurred with comparable frequency for both stent types during the early, late, and very late time periods (Table 3 and Figure 4 ). Beyond 1 year, the annual rate of Academic Research Consortium definite ST was 0.67% (95% confidence interval, 0.31% to 1.03%) for SES and 0.62% (95% confidence interval, 0.27% to 0.97%) for PES.
Angiographic Outcomes
Long-term angiographic follow-up was performed in 444 patients with 567 lesions at a median of 4.8 years for SES (interquartile range, 4.5 to 5.1) and 4.8 years for PES (interquartile range, 4.6 to 5.1) ( Figure 1 ). Serial angiographic follow-up at baseline, 8 months, and 5 years was available in 293 patients with 382 lesions. Baseline clinical and procedural characteristics in patients undergoing paired angiography were balanced except for a lower preprocedural MLD and higher percent diameter stenosis in SES-compared with PES-treated patients (Tables II and III in the online-only Data Supplement). Patients undergoing paired angiography were younger (PϽ0.01), more frequently male (PϽ0.01), and less frequently diabetic (Pϭ0.01) or hypertensive (Pϭ0.03) than patients not undergoing paired angiography. Angiographic findings in patients undergoing paired angiography are presented in Table 4 . In-stent MLD decreased from 2.69Ϯ0.39 mm after the procedure to 2.58Ϯ0.43 mm at 8 months (PϽ0.001) and to 2.25Ϯ0.77 mm at 5 years (PϽ0.001) in the overall population ( Figure 5 ). In-stent LL at 8 months among TLR-free patients amounted to 0.09Ϯ0.18 mm for SES and to 0.13Ϯ0.22 mm for PES (Pϭ0.03). At 5 years, in-stent loss increased to Unstable angina, n (%) 28 (6) 30 (6) Non-ST-segment elevation MI, n (%) 112 (22) 123 (24) ST-segment elevation MI, n (%) 117 (23) 110 (22) Glycoprotein IIb/IIIa antagonists, n (%) 171 (34) 147 (29) Multivessel disease, n (%) 300 (60) 301 (59) Left ventricular ejection fraction, meanϮSD, % 57Ϯ12 57Ϯ12
MI indicates myocardial infarction. (Table 4 ). Angiographic analysis of all patients undergoing angiography at 5 years (nϭ444, paired and unpaired) yielded similar results and is summarized in Table IV in the online-only Data Supplement. The P values for interaction are for differences in hazard ratios between 0 to 1 and 1 to 5 years. CI indicates confidence interval; MI, myocardial infarction; TLR, target lesion revascularization; SES, sirolimus-eluting stents; and PES, paclitaxeleluting stents.
Discussion
The clinical and angiographic outcome of the 2 firstgeneration DES (SES and PES) in the context of an allcomers randomized trial during long-term follow-up to 5 years has the following findings: (1) The superiority of SES over PES in terms of MACE and TLR at 1 year was no longer apparent at 5 years of follow-up; (2) revascularization of the target lesion beyond 1 year occurred at a low and stable rate of 1.7% per year; (3) luminal LL continued to increase over time and was similar for both stent types at 5-year angio-graphic follow-up; and (4) very late definite ST occurred at a steady rate of 0.65% per year, with no difference between stent types. Therapeutic differences between the 2 first-generation DES have been addressed in numerous randomized trials. Angiographic studies have consistently shown superior reduction of neointimal hyperplasia afforded by SES. In contrast, individual clinical trials comparing SES and PES have reported mixed results, although the synthesis of the available evidence as summarized in several meta-analyses suggests a lower risk of TLR with SES. 3 The superior suppression of neointimal hyperplasia and lower risk of restenosis associated with SES have been attributed to differences in the mode of action of the therapeutic agent, 14 and have been confirmed more recently with other limus analogues. 15 However, previous studies comparing SES with PES reported angiographic outcomes at 6 to 8 months, and the longest available clinical follow-up is limited to 2 years. 16 The present study provides additional information by extending the follow-up to 5 years in a randomized trial investigating the unrestricted use of SES and PES. We observed a time-by-treatment interaction for MACE and TLR, with hazard ratios Ͻ1 during the first year after randomization, but hazard ratios Ͼ1 in subsequent years. The differential catch-up led to a decrease of the advantage of SES over PES over time. Therefore, conventional levels of statistical significance were no longer reached at 5 years for the primary outcome, even though some advantages of SES over PES in terms of target vessel revascularization continued to be apparent up to 5 years.
The clinical findings are supported by the analysis of patients undergoing paired angiography at 8 months and 5 years. Although SES showed lower LL than PES at 8 months, a similar suppression of neointimal hyperplasia with both stent types was noted at 5 years. SES appear to lose the initial advantage in suppression of neointimal hyperplasia over PES, which may be related to differences in drug release kinetics, differential recovery of the cell cycle of quiescent smooth muscle cells, and differences in vascular healing. SES release 80% of the drug during the first 30 days, with nearly all drug eluted at 3 months, whereas PES release only 10% of the drug during the early phase, with the remainder permanently sequestered within the durable polymer. Previous serial angiographic studies of nonrandomized cohorts support the notion that luminal LL continues to accrue with firstgeneration DES and that delayed LL of SES numerically exceeds that observed with PES. 17 However, the risk of TLR in the present study of patients with percutaneous coronary intervention of multiple lesions amounted to only 1.7% per year, which is well in agreement with previous studies comparing DES with BMS in lower-risk patient populations. The risk of TLR was even lower (1.2% per year) when revascularization events related to the treatment of ST were subtracted.
We observed no difference in rates of death and MI between SES and PES throughout 5 years. These event rates are comparable to the long-term results of the treatment of de novo coronary disease using a single paclitaxel-eluting stent (TAXUS IV), 18 sirolimus-eluting stent in coronary lesions (SIRIUS), 19 and randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization (RAVEL) 20 studies, suggesting similar outcomes between early-generation DES and BMS. Randomized, controlled trials with extended follow-up to 5 years comparing early-generation DES with BMS reported a cumulative incidence of very late definite ST of up to 0.8% during the time period between 1 and 5 years. 19 -21 Similar low event rates of very late definite ST have been observed in the drug-eluting stents in the real world-LATE registry (DESIRE-LATE) 22 and Japanese Cypher 23 registries. In contrast, we report a 3-fold higher cumulative incidence of very late definite ST. The higher incidence in the present study is likely related to the unrestricted use of DES in an all-comers population with inclusion of patients with acute coronary syndromes as well as multivessel disease. Three-year follow-up data from the all-comers biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS) trial comparing SES with a new-generation biolimus-eluting stent 24 as well as from the percutaneous coronary intervention versus coronaryartery bypass grafting for severe coronary artery disease (SYNTAX) trial comparing PES with surgical revascularization 25 suggest a cumulative incidence of very late ST of 0.9% for SES (0.45% annual rate) and 0.6% for PES (annual rate) between 1 and 3 years. Moreover, acute MI has been identified as independent predictor of very late ST, 26 results in an increased incidence of late acquired stent malapposition, 27 and has been associated with more extensive inflammation and a higher proportion of uncovered struts compared with stable lesions after DES implantation. 11 Human autopsy studies 28 and recent clinical investigations of thrombosed DES specimens 29 imply delayed healing and vessel remodeling owing to chronic inflammation as potential mechanisms leading to this adverse event. Delayed healing has been characterized by lack of endothelialization and persistent fibrin deposition and has been identified as the principal pathological finding distinguishing early-generation DES with late thrombosis from patent DES. 28 Findings of delayed healing in early-generation DES have been complemented by in vivo imaging studies with the use of angioscopy 30 and optical coherence tomography. 31 The angiographic results of the present study may contribute to a mechanistic explanation of the ongoing risk of very late ST. The increase in luminal LL between 8 months and 5 years may be an expression of the ongoing healing process owing to chronic inflammation that clinically can manifest as very late ST.
The clinical implications of our study are as follows: First, the risk of repeat revascularization with first-generation DES is low despite evidence of an angiographic catch-up phenomenon. Second, very late ST remains an important limitation of first-generation DES and accounts for more than half of all MIs between 1 and 5 years. Finally, the continuous increase in LL in conjunction with the ongoing risk of very late ST suggests that vascular healing remains incomplete up to 5 years after implantation of first-generation DES. This may have important implications for the duration of dual antiplatelet therapy in patients treated with first-generation DES.
Limitations
The study has the following limitations. The implementation of protocol-mandated angiography at 2 time points may inflate rates of repeat revascularization. We attempted to address this by reporting rates of both ischemia-driven TLR and overall TLR. In addition, estimates of hazard ratios comparing stent types in patients without 5-year follow-up angiography were compatible with estimates calculated in patients with follow-up angiography. Revascularization procedures remote from the target vessel were not part of the present analysis, although they may be an important part of the overall need for revascularization in routine clinical practice because of disease progression. Because the angiographic evaluation was performed at 2 distinct time points rather than on an annual basis, we cannot determine the dynamics of temporal changes in lumen remodeling.
Conclusions
Long-term follow-up of first-generation DES shows no significant differences in clinical and angiographic outcomes between SES and PES. The continuous increase in luminal LL in conjunction with the ongoing risk of very late ST suggests that vascular healing remains incomplete up to 5 years after implantation of first-generation DES.
